BACULOVIRAL VECTORS COMPRISING REPEATED CODING SEQUENCES WITH DIFFERENTIAL CODON BIASES

(19)

(11)

EP 3 093 345 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	24.07.2019 Bulletin 2019/30

(45)	Mention of the grant of the patent:
	24.04.2019 Bulletin 2019/17

(21)	Application number: 16176100.2

(22)	Date of filing: 25.07.2008

(51)

International Patent Classification (IPC):

C07K 14/005^(2006.01)

C12N 7/00^(2006.01)

(54)	BACULOVIRAL VECTORS COMPRISING REPEATED CODING SEQUENCES WITH DIFFERENTIAL CODON BIASES BACULOVIRUS-VEKTOREN MIT WIEDERHOLTEN CODIERUNGSSEQUENZEN MIT DIFFERENTIELLEN CODON-VORSPANNUNGEN VECTEURS BACULOVIRAUX COMPORTANT DES SÉQUENCES DE CODAGE RÉPÉTÉES AVEC DES POLARISATIONS DE CODONS

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA MK RS

(30)

Priority:

26.07.2007 US 952081 P
26.07.2007 EP 07113257

(43)	Date of publication of application:
	16.11.2016 Bulletin 2016/46

(60)	Divisional application:
	19170381.8

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	08779058.0 / 2173888

(73)	Proprietor: UniQure IP B.V.
	1105 BP Amsterdam (NL)

(72)	Inventors:
	Bakker, Andrew Christian 1105 BP Amsterdan (NL) Hermens, Wilhelmus Theodorus Johannes Maria Christiaan 1105 BP Amsterdam (NL)

(74)	Representative: Nederlandsch Octrooibureau
	P.O. Box 29720 2502 LS The Hague 2502 LS The Hague (NL)

(56)

References cited: :

US-A1- 2003 228 696

URABE M ET AL: "Insect cells as a factory to produce adeno-associated virus type 2 vectors", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 13, no. 16, 1 November 2002 (2002-11-01), pages 1935-1943, XP002394454, ISSN: 1043-0342
KOHLBRENNER ET AL: "Successful Production of Pseudotyped rAAV Vectors Using a Modified Baculovirus Expression System", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 12, no. 6, December 2005 (2005-12), pages 1217-1225, XP005176630, ISSN: 1525-0016

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).